BNGOHealthcare · Medical Instruments & SuppliesThe 1 Wall Street analysts covering Bionano Genomics, Inc. hold a median 12-month price target of $4 — +236.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bionano Genomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (23): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BNGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +236.1% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $6.00 |
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 May 2025 | Maxim Group | Upgrade | Buy | — |
| 9 Apr 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 2 Apr 2025 | Scotiabank | Maintains | Sector Perform | — |
| 15 Nov 2024 | Ladenburg Thalmann | Downgrade | Neutral | — |
| 10 Sept 2024 | BTIG | Downgrade | Neutral | — |
| 28 Aug 2024 | Scotiabank | Downgrade | Sector Perform | $6.00 → $1.00 |
| 16 May 2024 | BTIG | Maintains | Buy | — |
| 7 Mar 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 10 Aug 2023 | BTIG | Maintains | Buy | — |
| 9 June 2023 | BTIG | Maintains | Buy | — |
| 25 May 2023 | EF Hutton | Initiates | Buy | $1.75 |
| 18 May 2023 | BTIG | Maintains | Buy | $3.00 → $2.00 |
| 24 Apr 2023 | BTIG | Maintains | Buy | — |
| 10 Mar 2023 | BTIG | Maintains | Buy | — |
| 6 Feb 2023 | Oppenheimer | Maintains | Outperform | $12 → $9.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BNGO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Bionano Genomics, Inc. returned −30.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 79% of US stocks
Cheaper than 84% of US stocks
Cheaper than 66% of US stocks
Higher than 70% of US stocks
Higher than 60% of US stocks
Higher than 65% of US stocks
Higher than 14% of US stocks
Higher than 6% of US stocks
Higher than 15% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bionano Genomics, Inc. has a market value of $16.6M and an enterprise value of $10.8M.
Revenue in the twelve months to 30 June 2026: $30.2M. The latest quarter grew 21.4% year on year.
Net income over the same four quarters: −$32.2M, a −106.6% net margin.
Diluted earnings per share, trailing twelve months: $−3.01.
Free cash flow in the twelve months to 30 June 2026: −$20.5M.
Trailing P/E: 0.0×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Bionano Genomics, Inc. employs 95 people — $318K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bionano Genomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bionano Genomics announced it will report its third-quarter 2026 financial results and highlight recent corporate progress during a conference call and live webcast on November 10, 2026, at 4:30 p.m. Eastern Time.
Why it matters — BNGO watchers can note the scheduled date and time for the company’s quarterly results and corporate update.
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, announced the expansion of optical genome mapping-based diagnostic testing for hematologic malignancies at Memorial Sloan Kettering Cancer Center, following approval from the New York State Department of Health.
Why it matters — This reflects broader adoption of Bionano's OGM technology at a major cancer center through regulatory approval, which could expand the reach of its testing services.
Bionano announced three new peer-reviewed studies from independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute. The studies demonstrate that optical genome mapping uncovers clinically significant genomic alterations missed by conventional cytogenetics, with direct implications for risk stratification in myelodysplastic syndromes, acute myeloid leukemia, and therapy-related myeloid neoplasms.
Why it matters — Independent peer-reviewed evidence of OGM's ability to detect clinically significant genomic alterations in hematologic cancers could support broader clinical adoption of Bionano's technology.
Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, announced that MolDX has issued a proposed Local Coverage Determination (LCD) for Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic Neoplasms. MolDX assesses molecular diagnostic technologies on behalf of Medicare Administrative Contractors.
Why it matters — A proposed Medicare LCD could move Bionano's genome-wide test toward reimbursement coverage, potentially broadening the commercial market for its technology.
Bionano Laboratories announced that the New York State Department of Health has granted approval allowing clinical use of optical genome mapping (OGM) based lab developed tests (LDTs). These tests will be available at University of Rochester Medicine for patients with suspected genetic disease, reproductive disorders, and hematologic malignancies.
Why it matters — This regulatory approval enables clinical deployment of Bionano's OGM-based tests, expanding their commercial reach into a state with stringent regulatory requirements.
The 1 Wall Street analysts covering Bionano Genomics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Bionano Genomics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bionano Genomics, Inc. 76 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Bionano Genomics, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +236.1% from the last close, and Ticker Nerd's factor model ranks Bionano Genomics, Inc. 76 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bionano Genomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
Bionano Genomics, Inc. returned -30.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis.
The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026". Bionano Genomics announced it will report its third-quarter 2026 financial results and highlight recent corporate progress during a conference call and live webcast on November 10, 2026, at 4:30 p.m. Eastern Time.
Bionano Genomics Inc. is a life sciences instrumentation company focused on genome analysis. The company develops and commercializes optical genome mapping solutions, including the Saphyr and Stratys systems, along with consumables, sample-preparation kits, and software used to analyze structural variation and other genomic changes. Its platform is designed for researchers and clinicians working in basic, translational, and clinical research, supporting applications in cytogenetics, rare disease studies, reproductive health, prenatal genetics, and oncology research. Bionano Genomics also offers data analysis tools that help laboratories visualize, interpret, and report genomic findings across multiple platforms. Headquartered in San Diego, California and founded in 2003, Bionano Genomics serves customers in global research and clinical markets with an integrated workflow for genome mapping and interpretation.
CEO Dr. Albert A. Luderer Ph.D. · 95 employees · United States · https://bionano.com
